The Center for Biosimilars® recaps the top news for the week of February 4, 2019.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 4.
Number 5: Fresenius Kabi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for its biosimilar adalimumab.
Number 4: In a recent paper, Italian rheumatology providers called into question whether newly published results from the DANBIO registry can be used to guide non-medical switching.
Number 3: Researchers have provided detailed results from the phase 3 REFLECTIONS trial that found Pfizer's trastuzumab biosimilar to be equivalent to the EU reference.
Number 2: A recent white paper found that the assumption that Medicare Part B payment rates lead providers choose costlier treatments in order to benefit from larger add-on payments is incorrect.
Number 1: Mundipharma announced that it has launched Pelmeg, a biosimilar pegfilgrastim, in Germany, the Netherlands, and Ireland.
Finally, last week, our e-newsletter asked if drug makers should be required to disclose their research and development costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.